{"filings":[{"id":2006237,"accession_number":"0001193125-26-329528","cik":2042347,"company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","form_type":"8-K","filed_at":"2026-08-03T11:03:03+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seaport Therapeutics Q2 net loss $62.6M; cash $427.3M; GlyphAllo Phase 2b on track for 1H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.6M for Q2 2026 vs $15.1M in Q2 2025; increase driven by one-time IPO-related stock-based compensation.","Cash, cash equivalents, and investments of $427.3M as of June 30, 2026, expected to fund operations into 2029.","Phase 2b BUOY-1 trial of GlyphAllo in MDD on track; topline data expected in 1H 2027.","Positive Phase 1 data for GlyphAgo: 6.8-fold bioavailability increase vs unmodified agomelatine; Phase 2a in GAD planned for 2H 2026.","Completed upsized IPO in May 2026 raising $260M gross proceeds; Sharon Mates appointed to board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":996392681.43,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900198,"accession_number":"0001193125-26-260671","cik":2042347,"company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","form_type":"8-K","filed_at":"2026-06-08T11:11:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.","Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.","GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.","GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.","Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":996392681.43,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97448,"accession_number":"0001193125-26-204086","cik":2042347,"company_name":"Seaport Therapeutics, Inc.","ticker":"SPTX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Seaport Therapeutics adopts new charter authorizing 700M shares, completes IPO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed amended charter authorizing 700M total shares: 500M voting common, 200M non-voting common, 10M undesignated preferred.","Eliminated references to prior preferred stock series; Board may issue undesignated preferred in series.","Adopted amended bylaws with stockholder meeting procedures, advance notice proposals, and director nomination rules.","Charter and bylaw changes became effective upon IPO consummation on May 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":996392681.43,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}